

Facts


1. The Longevity Foundation was **founded in 1992**.
2. It supports **research** into some of the most debilitating diseases known to humankind, mainly **cancer and neuro-degeneration**.
3. These diseases are those caused by **auto-immunity, inflammation, and aging**.
4. **Researchers share their findings and collaborate**.
5. The research must lead to **practical, near-term treatments and cures**.
6. The researchers have found **treatments and cures that are the first of their kind** in the world.
7. **Over \$850,000 in direct research grants** have been made
8. **These grants have leveraged in over \$9 million** in research resources contributed by partner institutions such as M.D. Anderson, the University of Texas, other foundations, and the National Institutes of Health.
9. Every \$1 donated to The Longevity Foundation leverages over \$10 worth of additional research. **A donation of \$1,000 yields \$10,000 in research**.
10. **We pay the research institutions for direct costs only**. We pay no administrative, indirect, or overhead costs. The Longevity Foundation itself has only a part-time Administrator who works out of donated office space, with minimal fixed costs.



Patrick Howard and Bill Lynn, M.D.

History of The Longevity Foundation

The Longevity Foundation began in 1992 after Patrick Howard's family received a diagnosis that Patrick had an incurable, terminal genetic disorder known as A-T. With the help of Bill Lynn, M.D., scientists and supporters soon learned that A-T is probably the best known model for many degenerative diseases. Since 1992, The Longevity Foundation has supported research into some of the most debilitating diseases plaguing human kind, including cancer and neuro-degeneration associated with auto-immunity and aging.



“Collaborative biomedical research of cancer and degenerative diseases associated with auto-immunity, inflammation, and premature aging”

2315 Westforest Drive
Austin, Texas 78704
512-440-1018
www.TheLongevityFoundation.org

Current Research

M.D. Anderson-Science Park

Paul Wong, Ph.D.

Neuro-pathology with implications for Alzheimer's, Parkinson's, Huntington's, Lou Gehrig's disease, multiple sclerosis and A-T. Cancers deriving from uncontrolled inflammation.

Virginia Scofield, Ph.D.

Inflammatory bowel disease, Crohn's disease, stomach cancer

Mingshan Yan, Ph. D.

Lymphoma

John Di Giovanni, Ph. D.

Skin cancer/ melanoma

University of Texas at Austin

Nomeli Nuñez, Ph.D.

Diabetes, wound healing

Texas A & M University at College Station

George Stoica, Ph. D.

Neuro-pathology with implications for Alzheimer's, Parkinson's, Huntington's, Lou Gehrig's disease, multiple sclerosis, and A-T

Northwestern University

Richard Miller, Ph.D. and Wenan Qiang, M.D., Ph.D.

Multiple sclerosis

Colorado State University

Julie Gionfriddo, Ph.D.

Glaucoma

Results

***For the first time in the world**, our researchers have found a way to **prevent neuro-degeneration** in mice that would ordinarily become paralyzed by a virus. These findings are being tested in other neuro-degenerative disease models.

***Treatments appear to prevent glaucoma** in dogs. Tests are being repeated and expanded.

***Initial findings indicate that radiation damage** ordinarily leading to **skin cancer** can be **minimized**. Confirmatory tests are being conducted and analyzed.

***Deleterious neurological effects of diabetes** appear to have been **prevented** in mouse models.

***Conditions that cause stomach cancer** have been **prevented**.

***For the first time ever**, our researchers have discovered a way to **prevent lymphoma** in animal models predisposed to that disease.

***Many of our ground breaking successes** have involved applications of a drug originally developed in Russia that is known as GVT or mono-sodium luminol in the United States.

***We have supported research at M.D. Anderson's veterinary facility in Bastrop that proves mono-sodium luminol to be non-toxic** to animals.

Future Needs

***Continue and expand** current studies.

***A basic scientific study on inflammatory breast cancer** to be conducted by **Robin Fuchs-Young, Ph. D.** at M.D. Anderson-Science Park.

***A clinical trial on A-T**, the best known genetic model of degenerative disease associated with aging, to be conducted jointly by **Gerard Berry, M.D.** at the Harvard School of Medicine and **Seth Corey, M.D.** at M.D. Anderson Hospital in Houston.

***Clinical trials on neurological injuries and inflammatory bowel disease** to be overseen by **Tom Caven, M.D.**, Medical Director of University Brackenridge Hospital in Austin.



Bach Pharma owns the world-wide distribution rights to a Russian drug that our researchers have re-confirmed to be a powerfully potent anti-inflammatory that is also non-toxic. The drug, as manufactured in purer form by Bach Pharma outside of Russia, is known as GVT or mono-sodium luminol. Bach Pharma has freely donated supplies of the drug to our scientists and recently established an endowment fund within The Longevity Foundation in honor of Archie Stroup, father of Bach Pharma's board chairman, Dr. Steve Stroup of Nashville. Archie Stroup died in the spring of 2008 at the age of 98.